Cerlek S, Papa B, Katicić M, Colić-Cvrlje V, Mielenz H
J Int Med Res. 1981;9(2):148-51. doi: 10.1177/030006058100900212.
In seventy-five out-patients with gastric and duodenal ulcer a comparative double-blind trial with pirenzepin against placebo was performed. The dose was 50 mg pirenzepin daily or placebo respectively, the duration of treatment being 4 weeks. The healing effect of pirenzepin in duodenal ulcer patients could be proven endoscopically and was statistically significant when compared with placebo (p less than or equal to 0.05). Strong evidence for the therapeutic efficacy of pirenzepin could be further demonstrated in both duodenal and gastric ulcer patients by measuring the marked reduction of ulcer size, even though statistical difference against placebo in gastric ulcers was not fully achieved. Pirenzepin was well tolerated by all patients, except for a mild case of diarrhoea which occurred in one patient. No patient complained of dryness of the mouth or of blurred vision.
对75例胃和十二指肠溃疡门诊患者进行了哌仑西平与安慰剂的双盲对照试验。剂量分别为每日50mg哌仑西平或安慰剂，治疗期为4周。内镜检查证实哌仑西平对十二指肠溃疡患者有愈合作用，与安慰剂相比有统计学意义（p≤0.05）。通过测量溃疡大小的显著缩小，在十二指肠溃疡和胃溃疡患者中都能进一步证明哌仑西平有很强的治疗效果，尽管胃溃疡与安慰剂相比的统计学差异未完全达到。除1例患者出现轻度腹泻外，所有患者对哌仑西平耐受性良好。没有患者抱怨口干或视力模糊。
